SELL and GUCY1A1 Gene Polymorphisms in Patients with Unstable Angina

Damian Malinowski1, Magda Zawadzka2, Krzysztof Safranow3

  • 1Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, 70-111 Szczecin, Poland.

Biomedicines
|October 27, 2022
PubMed

Insights

Genetic variations in SELL and GUCY1A1 genes were studied for their link to unstable angina. Certain polymorphisms may influence risk in specific age groups within the Polish population.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Thrombosis Research

Background:

  • Acute coronary syndromes, like unstable angina, often stem from atherosclerotic plaque rupture and subsequent thrombus formation.
  • Genetic factors, including polymorphisms in genes regulating inflammation and vascular function, can influence the risk of developing coronary artery disease.
  • L-selectin (SELL) and Guanylate cyclase 1 soluble subunit alpha 1 (GUCY1A1) are implicated in leukocyte adhesion, inflammation, vasoreactivity, and platelet function, all relevant to thrombotic processes.

Purpose of the Study:

  • To investigate the association between specific polymorphisms in the SELL (rs2205849, rs2229569) and GUCY1A1 (rs7692387) genes and the risk of unstable angina pectoris.
  • To explore the relationship between these genetic polymorphisms and clinical parameters associated with ischemic heart disease risk.
  • To evaluate these associations within the Polish population.

Main Methods:

  • Genotyping of SELL rs2205849, rs2229569, and GUCY1A1 rs7692387 polymorphisms in 232 patients diagnosed with unstable angina.
  • Coronary angiography was used to confirm significant coronary artery stenosis (>70%) in patients.
  • Statistical analysis comparing genotype frequencies between patients and controls, with subgroup analysis based on age (55 years).

Main Results:

  • No significant differences in the overall distribution of GUCY1A1 rs7692387, SELL rs2205849, and SELL rs2229569 polymorphisms were observed between the unstable angina group and the control group.
  • In patients over 55 years, a decreased frequency of the GUCY1A1 rs7692387AA genotype and increased frequencies of SELL rs2205849 CC and SELL rs2229569 AA genotypes were noted in unstable angina patients.
  • Conversely, the GUCY1A1 rs7692387 polymorphism showed a potential increased risk in patients younger than 55 years.

Conclusions:

  • The studied SELL and GUCY1A1 polymorphisms are not general risk factors for unstable angina in the Polish population.
  • The GUCY1A1 rs7692387 polymorphism may be associated with an increased risk of unstable angina in individuals younger than 55.
  • SELL polymorphisms rs2205849 and rs2229569 might be linked to an increased risk of unstable angina in individuals older than 55 in the Polish population.

Related Concept Videos

Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
19
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
701
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
19
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
16
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
35
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
627